F4, a collagen XIX-derived peptide, inhibits tumor angiogenesis through αvβ3 and α5β1 integrin interaction.
Fiche publication
Date publication
décembre 2021
Journal
Cell adhesion & migration
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BRASSART-PASCO Sylvie, Dr MONBOISSE Jean-Claude, Pr RAMONT Laurent, Dr TERRYN Christine, Dr BRASSART Bertrand, Dr OUDART Jean-Baptiste
Tous les auteurs :
Oudart JB, Villemin M, Brassart B, Sellier C, Terryn C, Dupont-Deshorgue A, Monboisse JC, Maquart FX, Ramont L, Brassart-Pasco S
Lien Pubmed
Résumé
We previously demonstrated that F4 peptide (CNPEDCLYPVSHAHQR) from collagen XIX was able to inhibit melanoma cell migration and cancer progression in a mouse melanoma model. The aim of the present work was to study the anti-angiogenic properties of F4 peptide. We demonstrated that F4 peptide inhibited VEGF-induced pseudo-tube formation on Matrigel by endothelial cells and endothelial sprouting in a rat aortic ring assay. By affinity chromatography, we identified αvβ3 and α5β1 integrins as potential receptors for F4 peptide on endothelial cell surface. Using solid phase assays, we proved the direct interaction between F4 and both integrins. Taken together, our results demonstrate that F4 peptide is a potent antitumor agent inhibiting both angiogenesis and tumor cell migration.
Mots clés
Extracellular matrix, angiogenesis, collagen XIX, integrin, matrikine
Référence
Cell Adh Migr. 2021 Dec;15(1):215-223